Avinger Announces Pricing of $3.55 Million Registered

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
17
Avinger Announces Pricing of $3.55 Million Registered Direct Offering

REDWOOD CITY, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR ), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 2,166,180 shares of common stock at a price of $1.6425 per share in a registered direct offering, resulting in total gross proceeds of approximately $3.55 million. The Company also agreed to issue unregistered warrants to the investors in a concurrent private placement to purchase up to 0.5 share of common stock for each share purchased with an exercise price of $1.58 per share. The warrants will be exercisable six months following the closing date and will expire three years following the date of issuance. The closing of the sale of the securities is expected to take place on or about July 16, 2018, subject to the satisfaction of customary closing conditions.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., (NYSE American:LTS) is acting as exclusive placement agent for the registered direct offering and concurrent private placement.

The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-209368), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on March 8, 2016. The warrants and shares issuable upon exercise of the warrants were offered in a concurrent private placement and have not been registered under the Securities Act of 1933, as amended.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock will be filed by the Company with the SEC. When available, copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172 or by email at prospectus@ladenburg.com.

About Avinger, Inc. Avinger is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot family of chronic total occlusion (CTO) catheters, and the Pantheris ®  family of atherectomy devices. Avinger is based in Redwood City, CA. For more information, please visit www.avinger.com .

Forward-Looking Statements This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding Avinger’s financing and anticipated closing. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; our ability to demonstrate the benefits of our Lumivascular platform; the resource requirements related to Pantheris; the outcome of clinical trial results; potential exposure to third-party product liability, intellectual property and other litigation; lack of long-term data demonstrating the safety and efficacy of our Lumivascular platform products; experiences of high-volume users of our products may lead to better patient outcomes than those of physicians that are less proficient; reliance on third-party vendors; dependency on physician adoption; reliance on key personnel; and requirements to obtain regulatory approval to commercialize our products; as well as the other risks described in the section entitled “Risk Factors” and elsewhere in our quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2018. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward-looking statements.

Investor Contact: Mark Weinswig Chief Financial Officer Avinger, Inc. (650) 241-7916 ir@avinger.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 95

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 86

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 102

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 93

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 121

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
RazorMetrics' Fast 500 Run Merits a Harder Investor Look

Updated Category News Views 75

A 4,488% growth figure can make even a seasoned skeptic sit upright. RazorMetrics landed at No. 20 on Deloitte's 2026 Technology Fast 500 after ranking No. 12 in 2025, and it again took the top Texas slot. That is serious momentum for an Austin company working on one of healthcare's most stubborn expenses: prescription drugs. Still, this is healthcare cost containment,...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 111

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 72

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 139

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 119

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading

Top 5 Most Recently Viewed Articles

Ollie's Bargain Outlet Raises Over $1.3 Million for Charity

Updated Category News Views 216

Ollie's Bargain Outlet Makes a Difference this Holiday Season Ollie's Bargain Outlet recently announced an impressive fundraising effort, raising over $1.3 million for the Marine Toys for Tots Program. This initiative highlights the company's commitment to giving back to the community during the holiday season. From early November to early December, participating Ollie's...

Continue Reading
Navigating the Integer Holdings Corporation Class Action Concerns

Updated Category News Views 147

Your Rights as an Investor in Integer Holdings Corporation If you've invested in Integer Holdings Corporation (NYSE: ITGR), you might be feeling concerned about recent developments. The company, known for its role in cardiac rhythm management and cardiovascular product manufacturing, is currently under scrutiny due to allegations that it misled investors regarding the...

Continue Reading
Indochino Welcomes Sean Wrenn as New Vice President of Retail

Updated Category News Views 163

Indochino Welcomes Sean Wrenn as New Vice President of Retail INDOCHINO, the leader in made to measure apparel, has appointed Sean Wrenn as the new Vice President of Retail Sales and Operations. With over two decades of retail experience, Sean is set to enhance the company’s operations and customer engagement. Sean Wrenn's Background and Expertise Sean Wrenn joins...

Continue Reading
Innovative Partnership Enhances Efficiency in Dairy Processing

Updated Category News Views 200

Collaboration to Boost Dairy Processing Efficiency In an exciting development within the dairy processing sector, CADDi, a renowned provider of digital solutions for manufacturers, has teamed up with Dairy Conveyor Corporation (DCC Automation). This collaboration marks a significant step towards optimizing supply chains and fostering better communication across DCC's...

Continue Reading
Celebrating Food and Beverage Excellence in the Middle East

Updated Category News Views 171

Celebrating Excellence in Food and Beverage The Middle East Food & Beverage Excellence Awards is an annual event that brings together the best in the industry, turning the spotlight on the remarkable achievements of food and beverage professionals. Last night, at the stunning JW Marriott Marina, industry leaders in the Middle East gathered for an unforgettable evening...

Continue Reading